World Health Organization, WHO, has issued a stern warning against the circulation of counterfeit diabetes drugs, which it says is a problem affecting all regions of the world.
The health authority in a statement disclosed that the drugs have been in circulation since 2022, referred specifically to findings in Britain, the U.S. and Brazil since October 2023.
The drug concerns Ozempic, a medicine containing the active ingredient semaglutide, which is also approved in the EU for the treatment of type 2 diabetes.
The counterfeit version looks identical to the real medicine, because the product also suppresses the appetite, it is increasingly being prescribed for weight loss.
But counterfeit drugs may not contain the right amount of active ingredients and could therefore lead to uncontrolled sugar in diabetics, the WHO said.
READ ALSO:Â WHO announces global resurgence of cholera with over 1,900 deaths
It added that they may also contain other active ingredients that pose health risks.
The WHO called on doctors, pharmacists, regulatory authorities and the public to be vigilant.
The health organization cautioned that people should only buy medicines on prescription from pharmacies and not online.
“Users should ensure that the dosage scale on insulin pens is displayed correctly, the label looks correct and there are no spelling mistakes on the box,” it added.
Credible News.ng
